These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36449947)

  • 1. Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Cancer.
    Wan G; Feng Z; Zhang Q; Li X; Ran K; Feng H; Luo T; Zhou S; Su C; Wei W; Wang N; Gao C; Zhao L; Yu L
    J Med Chem; 2022 Dec; 65(24):16541-16569. PubMed ID: 36449947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
    Yang F; Zhao N; Song J; Zhu K; Jiang CS; Shan P; Zhang H
    Molecules; 2019 Jul; 24(14):. PubMed ID: 31311163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
    Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
    Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
    Wu S; Huang Y; Wang T; Li K; Lu J; Huang M; Dong G; Sheng C
    J Med Chem; 2022 Mar; 65(6):4818-4831. PubMed ID: 35238576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer.
    Ren Y; Li S; Zhu R; Wan C; Song D; Zhu J; Cai G; Long S; Kong L; Yu W
    J Med Chem; 2021 Jun; 64(11):7468-7482. PubMed ID: 34043359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
    Li X; Zhang Y; Jiang Y; Wu J; Inks ES; Chou CJ; Gao S; Hou J; Ding Q; Li J; Wang X; Huang Y; Xu W
    Eur J Med Chem; 2017 Jul; 134():185-206. PubMed ID: 28415009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and bioactivity evaluations of 8-substituted-quinoline-2-carboxamide derivatives as novel histone deacetylase (HDAC) inhibitors.
    Zhao Y; Yao Z; Ren W; Yang X; Hou X; Cao S; Fang H
    Bioorg Med Chem; 2023 May; 85():117242. PubMed ID: 37079967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis, and Structure-Activity relationships of Evodiamine-Based topoisomerase (Top)/Histone deacetylase (HDAC) dual inhibitors.
    Zhu F; Meng X; Liang H; Sheng C; Dong G; Liu D; Wu S
    Bioorg Chem; 2022 May; 122():105702. PubMed ID: 35286923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
    Cheng C; Yun F; He J; Ullah S; Yuan Q
    Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of quinazolinyl-containing benzamides derivatives as novel HDAC1 inhibitors with in vitro and in vivo antitumor activities.
    Zhang Z; Zhang Q; Zhang H; Jiao M; Guo Z; Peng X; Fu L; Li J
    Bioorg Chem; 2021 Dec; 117():105407. PubMed ID: 34653945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
    Luo G; Lin X; Ren S; Wu S; Wang X; Ma L; Xiang H
    Eur J Med Chem; 2021 Dec; 226():113870. PubMed ID: 34610548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors.
    Yamashita M; Tahara T; Hayakawa S; Matsumoto H; Wada SI; Tomioka K; Iida A
    Bioorg Med Chem; 2018 May; 26(8):1920-1928. PubMed ID: 29519604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
    Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
    Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel itaconimide-based derivatives as potent HDAC inhibitors for the efficient treatment of prostate cancer.
    Jiang Q; Tang Y; Hu Q; Wang B; Ruan X; Zhou Q
    Eur J Med Chem; 2024 Apr; 269():116315. PubMed ID: 38503167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDAC1/3 dual selective inhibitors - new therapeutic agents for the potential treatment of cancer.
    Li X; Xu W
    Drug Discov Ther; 2014 Oct; 8(5):225-8. PubMed ID: 25382558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
    Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
    Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation.
    Aboeldahab AMA; Beshr EAM; Shoman ME; Rabea SM; Aly OM
    Eur J Med Chem; 2018 Feb; 146():79-92. PubMed ID: 29396364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.
    Pojani E; Barlocco D
    Curr Med Chem; 2021; 28(7):1290-1303. PubMed ID: 32013816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
    Liang X; Zang J; Li X; Tang S; Huang M; Geng M; Chou CJ; Li C; Cao Y; Xu W; Liu H; Zhang Y
    J Med Chem; 2019 Apr; 62(8):3898-3923. PubMed ID: 30901208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
    Zhang Z; Hou S; Chen H; Ran T; Jiang F; Bian Y; Zhang D; Zhi Y; Wang L; Zhang L; Li H; Zhang Y; Tang W; Lu T; Chen Y
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2931-2935. PubMed ID: 27142751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.